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Abstract
Background: Variations in corticosteroid/anesthetic doses for injecting shoulder conditions were examined among orthopaedic
surgeons, rheumatologists, and primary-care sports medicine (PCSMs) and physical medicine and rehabilitation (PMRs) physicians
to provide data needed for documenting inter-group differences for establishing uniform injection guidelines.
Methods: 264 surveys, sent to these physicians in our tri-state area of the western United States, addressed corticosteroid/
anesthetic doses and types used for subacromial impingement, degenerative glenohumeral and acromioclavicular arthritis, biceps
tendinitis, and peri-scapular trigger points. They were asked about preferences regarding: 1) fluorinated vs. non-fluorinated
corticosteroids, 2) acetate vs. phosphate types, 3) patient age, and 4) adjustments for special considerations including young
athletes and diabetics.
Results: 169 (64% response rate, RR) surveys were returned: 105/163 orthopaedic surgeons (64%RR), 44/77 PCSMs/PMRs
(57%RR), 20/24 rheumatologists (83%RR). Although corticosteroid doses do not differ significantly between specialties (p > 0.3),
anesthetic volumes show broad variations, with surgeons using larger volumes. Although 29% of PCSMs/PMRs, 44%
rheumatologists, and 41% surgeons exceed "recommended" doses for the acromioclavicular joint, >98% were within
recommendations for the subacromial bursa and glenohumeral joint. Depo-Medrol® (methylprednisolone acetate) and Kenalog®
(triamcinolone acetonide) are most commonly used. More rheumatologists (80%) were aware that there are acetate and phosphate
types of corticosteroids as compared to PCSMs/PMRs (76%) and orthopaedists (60%). However, relatively fewer rheumatologists
(25%) than PCSMs/PMRs (32%) or orthopaedists (32%) knew that phosphate types are more soluble. Fluorinated corticosteroids,
which can be deleterious to soft tissues, were used with these frequencies for the biceps sheath: 17% rheumatologists, 8% PCSMs/
PMRs, 37% orthopaedists. Nearly 85% use the same non-fluorinated corticosteroid for all injections; <10% make adjustments for
diabetic patients.
Conclusion: Variations between specialists in anesthetic doses suggest that surgeons (who use significantly larger volumes)
emphasize determining the percentage of pain attributable to the injected region. Alternatively, this might reflect a more profound
knowledge that non-surgeons specialists have of the potentially adverse cardiovascular effects of these agents. Variations between
these specialists in corticosteroid/anesthetic doses and/or types, and their use in some special situations (e.g., diabetics), bespeak
the need for additional investigations aimed at establishing uniform injection guidelines, and for identifying knowledge deficiencies
that warrant advanced education.
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Background
Injectable corticosteroids are commonly used by ortho-
paedic surgeons, rheumatologists, primary-care physi-
cians and other health-care providers in the treatment of
painful shoulder conditions. However, surveys have esti-
mated that 60% to 70% of internists finishing their resi-
dency training feel that they need more training in
performing these injections [1]. Furthermore, even
though corticosteroid injections are commonly used for
painful shoulder conditions, there are no uniform guide-
lines regarding dosage and other aspects of their adminis-
tration. In order to work towards this goal, baseline
information regarding corticosteroid usage is needed. We
were not able to locate published data comparing and
contrasting surgeon and non-surgeon musculoskeletal
specialists who treat painful shoulder conditions with
these injections. Additionally, our literature review of
studies (including meta-analyses) evaluating the use of
corticosteroid injections for painful shoulder conditions
show a lack of consensus regarding their dosing and time
course of administration [2-12] (Table 1). Among these
reviews, we also observed that confusion often arises
regarding dosing when making a direct correlation
between equivalences and relative potencies of corticos-
teroids (Tables 2 and 3). This lack of uniform injection
guidelines is important because deleterious consequences
and other sequelae, both systemic and local, can result
from corticosteroid injections, especially from chronic
use, large doses, and errant injection (e.g., into a tendon)
[13].
The goal of this study is to evaluate current trends of
injectable corticosteroid use among orthopaedic surgeons
and selected non-surgeon sub-specialists and specialty
physicians (rheumatologists, primary-care sports medi-
cine physicians, and physical medicine and rehabilitation
physicians) for injecting degenerative and overuse shoul-
der conditions in order to provide data that will ulti-
mately be needed to establish uniform guidelines and
identify potential knowledge deficiencies. We focused on
these physicians in our tri-state referral area (Utah, Idaho,
Wyoming; population = ~4.5 million people) in the west-
ern United States. We hypothesize that: 1) there are signif-
icant differences in types and doses of corticosteroid and
local anesthetic used for shoulder injections within and
between surgical and non-surgical specialists who treat
various painful shoulder conditions, and 2) doses of cor-
ticosteroid and local anesthetic administered in shoulder
injections often fall outside presently recommended
ranges. Additional considerations included questions
regarding: 1) the use of fluorinated vs. non-fluorinated
corticosteroids, 2) the use of acetate vs. phosphate types,
3) the rationale for using a particular corticosteroid, 4)
adjustments regarding patient age, and 5) adjustments for
special considerations including young athletes and dia-
betics.
Table 1: Various recommended corticosteroid dose ranges. Currently Recommended Corticosteroid ("Cortisone") Dose Ranges
Generic Name (Tradename) Intermediate Jointa 
(mg) [A-C Joint]
Large Jointa (mg) [S-A 
Bursa and G-H Joint]
References
Methylprednisolone diacetate (Depo-Medrol®) - 40–60 Cush and Kavanaugh (2000)6
20–30 40–80 Greene (2001)7
20–40 40–80 Tallia and Cardone (2003)3
- 20–80 Noerdlinger and Fadale (2001)2
Prednisolone tebutate (Hydeltra-TBA®)5 – 5 0 b 5–50b Cush and Kavanaugh (2000)6
- 10–40 Noerdlinger and Fadale (2001)2
Triamcinolone acetonide (Kenalog®)5 – 4 0 b 5–40b Cush and Kavanaugh (2000)6
10 20 Saunders (2002)4
- 5–40 Noerdlinger and Fadale (2001)2
10–20 40–80 Moore (2001)8
Triamcinolone hexacetonide (Aristospan®)5 – 4 0 b 5–40b Cush and Kavanaugh (2000)6
- 10–20 Noerdlinger and Fadale (2001)2
Betamethasone sodium phosphate – 
Betamethasone acetate (Celestone Soluspan®)
1.5–6b 1.5–6b Cush and Kavanaugh (2000)6
1.5–3 6–12 Tallia and Cardone (2003)3
- 6–12 Noerdlinger and Fadale (2001)2
a "Intermediate joints" = A-C, elbow, wrist, temporal mandibular, and ankle; "Large joints" = S-A bursa, G-H, hip, and knee (Source: Current 
Procedural Terminology (CPT) 2004, American Medical Association, AMA Press)
b The authors listed suggested these general ranges for both intermediate and large joints.BMC Musculoskeletal Disorders 2007, 8:63 http://www.biomedcentral.com/1471-2474/8/63
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Methods
We conducted a survey by mail of orthopaedic surgeons
(n = 163), rheumatologists (n = 24), and specialty physi-
cians [PCSMs = primary-care sports medicine physicians,
and PMRs = physical medicine and rehabilitation physi-
cians ("physiatrists") (n = 77)] in Utah, Idaho, and Wyo-
ming regarding their use of corticosteroid for painful
shoulder conditions. These physicians (surgeons and
non-surgeons) practice within the referral area of our
orthopaedic shoulder-specialty practice in Salt Lake City,
Utah, USA. The mailing addresses were obtained from
membership directories of the American Academy of
Orthopaedic Surgeons, the Utah, Idaho, and Wyoming
Medical Associations, and regional telephone directories.
Each physician was sent a cover letter, which was attached
to the survey, that explicitly stated that the survey was
designed to obtain information regarding the corticoster-
oid and local anesthetic doses used for injecting painful
degenerative and overuse conditions, strains (e.g., acromi-
oclavicular joint), and related peri-scapular trigger points.
Inflammatory conditions such as rheumatoid and lupus
arthritis were expressly excluded. Trigger points were also
defined as discrete, focal, hyperirritable foci located in
taut peri-scapular musculature [14]. Each physician was
asked 14 questions (see Appendix), including which types
and amounts of corticosteroid(s) and local anesthetic(s)
that they use when injecting five areas/diagnoses of the
shoulder: the subacromial (S-A) bursa, acromioclavicular
(A-C) joint, glenohumeral (G-H) joint, biceps tendon
sheath, and peri-scapular trigger points. Other questions
dealt with differences between acetate and phosphate cor-
ticosteroid types, fluorinated and non-fluorinated types,
and whether or not the physicians used specific corticos-
teroid types when injecting some types of patients or
patients with specific medical conditions (i.e., younger
athletes or diabetics). Physicians were queried specifically
about diabetic patients, and were asked to indicate any
Table 2: Common injectable corticosteroids. Common Injectable Corticosteroids ("Cortisones")
Recommended Dose Rangec








Large 'Joint' [S-A Bursa 
and G-H Joint] (mg)
Most Soluble
* Betamethasone sodium phosphate Celestone PhosphateF 3 25 1.5–3 6–12
Soluble
* Dexamethasone sodium 
phosphate
DecadronF 4 25 2–4 7.5–15
Prednisone sodium phosphate Hydeltrasol 20 4 12.5–25 50–100
Slightly Soluble
* Methylprednisolone acetate Depo-Medrol 20/40/80 5 10–20 40–80
Triamcinolone diacetate Aristospan ForteF 25/40 5 10–20 40–80
Prednisolone tebutate Hydeltra-TBA 20 4 12.5–25 40–80
Relatively insoluble
* Triamcinolone acetonide KenalogF 10/40 5 10–20 40–80
* Triamcinolone hexacetonide AristospanF 20 5 10–20 40–80
Hydrocortisone acetate Hydrocortone 25 1 25–50d 100–200d
Dexamethasone acetate Decadron-LAF 8 25 2–4 7.5–15
Combination
* Betamethasone sodium 
phosphate-Betamethasone acetate
Celestone SoluspanF 6 25 1.5–3 6–12
Chart adapted from: Noerdlinger and Fadale (2001)2, Saunders (2002)4, Tallia and Cardone (2003)3, Axelrod (1976)10, and Klippel et al. (2001)9.
* The most commonly used cortisones among the physicians surveyed in the present study.
F = fluorinated compounds.
a Adjustments in reported "cortisone" volumes (doses) in our survey respondents were made in cases where different strengths are available. In 
these cases the volumes reported in the results section are: 40 mg/cc for Depo-Medrol, Aristospan Forte, and Kenalog; 25 mg/cc for 
Hydrocortone.
b For example, 1 mg Celestone = 5 mg Depo-Medrol = 5 mg Aristospan = 25 mg Hydrocortisone (See Table 3).
c The dose equivalents for some "Large Joint" doses are derived from Klippel et al. (2001)9 and Noerdlinger and Fadale (2001)2. A-C joint ranges are 
adapted from Saunders (Kenalog), and Tallia and Cardone (Depo-Medrol, Celestone Soluspan). Doses for other cortisone types not conisderered 
in these sources are derived from the dose equivalents shown above, with some corrections for inconsistencies in Noerdlinger and Fadale (2001) 2.
d These values are estimated.BMC Musculoskeletal Disorders 2007, 8:63 http://www.biomedcentral.com/1471-2474/8/63
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other patients or medical conditions for which they made
modifications in corticosteroid types, or for which they
chose not to administer these injections. The content of
the questions were derived from a literature review of
Cochrane databases[15] and various other sources, several
of which are referenced in the body of the present study
[2,16-18]. Most questions were posed in a close-ended
format in accordance with Dillman (2000) for this form
of behavioral survey [19]. Six weeks after the first mailing,
a second mailing was made to non-responding physicians
to increase the response rate. There were no inducements
for returning the survey. Results were compiled four
months after the initial mailing.
A subsequent analysis was conducted six to nine months
after the initial mailing in order to assess possible differ-
ences between responders and non-responders in the two
groups with less than 65% response rate (orthopaedic sur-
geons and PCSM/PMR physicians). This was accom-
plished by sending surveys to non-responders with a
transmittal letter from the principal investigator that
stated: 1) the importance of the study, and 2) that comple-
tion of their survey is essential for ensuring statistical reli-
ability of the study. From these groups of non-responders,
11 additional surveys were obtained from orthopaedic
surgeons and seven from the PCSM/PMR physicians.
Results of these surveys from these 'late-responders' (from
the third mailing) were compared to the entire group of
'early responders' (from the first two mailings) in each
group.
It should be noted that Celestone Soluspan® (Betametha-
sone sodium phosphate-Betamethasone acetate) was not
commercially available in the U.S. at the time that the sur-
Table 3: Relative glucocorticoid potencies, and relative prednisone or glucocorticoid equivalents (per mg). Relative Glucocorticoid 
Potencies*, and Relative Prednisone or Glucocorticoid Equivalents For Intra-synovial Injections




Decadron Decadron L.A. Kenalog Aristospan Depo-Medrol Hydeltra T.B.A Hydro-
cortisone










25 25 25 5 5 5 4 1
Greene (2001)7 Glucocorticoid 
Potency
25 - - 5 5 4 4 1









25 30 - 5 5 5 4 1
Bird (2003)37 Glucocorticoid 
Potency





25 - - 5 - 5 4 1
B. Prednisone Equivalence (in mg prednisone)
Owen (2001)32 Prednisone 
Equivalence
10 8 - 10 5 10 4 1
Wise (2005)1 Prednisone 
Equivalence
10 8 16 10 5 10 4 1
















0.6 - - 4 4 4 5 -
Relative Potencies Used in 
Current Study (See Table 2):
25 25 25 5 5 5 4 1
* The values listed for glucocorticoid ("cortisone") potencies are relative; hydrocortisone is arbitrarily assigned a value of 1. Axelrod (1976, 1979) 
10,11 is the only listed author that provides extensive sources for this information.
In Part A "Relative Potencies" should be read in the following manner: Celestone Soluspan is 25 times more potent then Hydrocortisone, and 
Kenalog is 5 times more potent than Hydrocortisone, and etc.
Note: Confusion often arises when making direct correlation between mg equivalence and relative potencies. They are typically inversley related. 
However, relative solubility variations can also influence these values in ways that are not yet fully understood.BMC Musculoskeletal Disorders 2007, 8:63 http://www.biomedcentral.com/1471-2474/8/63
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vey was administered. Some physicians, however, had this
product in their clinics, and therefore they were still using
it when they were surveyed. Finally, all dosages that are
reported as "volumes" of corticosteroid (in cc) are nor-
malized to 40 mg/ml of Depo-Medrol®  (Methylpred-
nisolone acetate) (Table 2). Corticosteroid doses were
considered "excessive" when they exceeded the ranges
shown in table 2.
Statistical analysis
For the observed sample sizes of n = 105 orthopaedic sur-
geons, n = 44 PCSMs/PMRs, and n = 20 rheumatologists,
a post-hoc power analysis was conducted, based on a two-
sided, alpha 0.05 comparison. For comparisons of contin-
uous variables, the study had at least 95% power to detect
a one standard deviation difference in means between any
of the three groups. For a one-half standard deviation dif-
ference, there was 80% power for the orthopaedic sur-
geons vs. PCSMs/PMRs comparison, and approximately
50% for the other two comparisons. For comparisons of
categorical variables, to detect an absolute difference
between groups of 30% vs. 60%, in "yes" responses for
example, the study had 90% power for the orthopaedic
surgeons vs. PCSMs/PMRs comparison, 64% power for
the orthopaedic surgeons vs. rheumatologists compari-
son, and 50% power for the PCSMs/PMRs vs. rheumatol-
ogist comparison. For a difference of 20% or smaller, no
group comparison exceeded 57% power. Thus, the study
was adequately powered to detect moderately large differ-
ences between means, but was inadequately powered to
detect smaller, but reasonable group differences for cate-
gorical variables.
For pairwise comparisons of groups on continuous varia-
bles, such as corticosteroid doses and local anesthetic vol-
umes, a two-sample t test was used. For pairwise
comparisons of categorical variables, a chi-square test was
used. Spearman correlation was used to test for an associ-
ation between corticosteroid and local anesthetic volumes
and an ordered categorical measurement of physician
years of clinical practice, scored as (0–5 years = 1, 6–10
years = 2, 11–15 years = 3, 16–20 years = 4, >20 years = 5).
Comparisons of early responders with late responders
where similarly made. Given the already low power of the
study, no adjustment was made for multiple comparisons.
All statistical comparisons were made using Statview sta-
tistical software (SAS Institute, Cary, NC, USA). Signifi-
cance was set at p < 0.05.
Results
Of the 264 surveys that were mailed, 169 usable surveys
were returned (64% overall response rate) from the early
responders (data reported here are from early responders;
see below for results of early vs. late responder analyses),
including 105/163 orthopaedic surgeons (64% response
rate), 44/77 PCSMs/PMRs (57% response rate), and 20/
24 rheumatologists (83% response rate). Of the respond-
ing physicians, 150 (89%) treat painful shoulder condi-
tions with corticosteroid injections; the most common
locations being the S-A bursa (97%) and the A-C joint
(83%). The type of corticosteroid and the percentage of
physicians who inject the S-A bursa are shown in figure 1.
These trends were commensurate with the other three
shoulder regions, although fewer total physicians inject
the G-H joint (76.4%), the biceps tendon sheath (67.3%),
and peri-scapular trigger points (58.7%). Relative fre-
quencies within each group of the two most commonly
injected corticosteroids, or corticosteroid combinations,
for the A-C and G-H joints, and S-A bursa are shown in
Table 4.
Data regarding gender and years-in-practice are summa-
rized in Table 5. For all injected locations in the two
groups with males and females (PCSMs/PMRs and rheu-
matologists), there were no significant male vs. female dif-
ferences (all p values > 0.49) in corticosteroid doses and
local anesthetic volumes. Using combined data from the
three physician groups for each of the five injected loca-
tions, corticosteroid doses and local anesthetic volumes
showed little or no correlation with years in practice (the
absolute values of all ten r values are ≤ 0.238 with only
one p value < 0.05). Analysis of each of the three physi-
cian groups yielded similar results for: 1) the orthopaed-
ists for corticosteroid and local anesthetic injections (the
absolute values of all ten r values are ≤ 0.206 and all p val-
ues ≥ 0.07); 2) the PCSMs/PMRs for local anesthetic vol-
umes only (the absolute values of all five r values are <
0.210 and all p values > 0.3); and 3) the rheumatologists
for local anesthetic volumes only (the absolute values of
all five r values are < 0.340 and all p values > 0.4). In con-
trast, years-in-practice and corticosteroid doses showed
significant (p ≤ 0.05), or tendencies toward significant
(0.05 < p ≤ 0.12), inverse relationships in the: 1) PCSMs/
PMRs, with these r values ranging from -0.327 (G-H joint,
p = 0.12) to -0.466 (A-C joint, p = 0.04); and 2) rheuma-
tologists, with these r values ranging from -0.533 (S-A
bursa, p = 0.01) to -0.759 (trigger points, p = 0.05).
Early-responder vs. late-responder analysis did not dem-
onstrate significant differences (p > 0.1) within each of the
two groups with response rates of <65% (orthopaedic sur-
geons and PCSMs/PMRs).
Hypothesis 1
Although there is variability between specialties in the
type of corticosteroid used for injecting painful shoulder
conditions, there was no statistically significant difference
in the doses used between the specialties for any particular
joint injection (p > 0.3 for all inter-group comparisons for
each injected location). This refutes the first facet of ourBMC Musculoskeletal Disorders 2007, 8:63 http://www.biomedcentral.com/1471-2474/8/63
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first hypothesis. In contrast, the volumes of local anes-
thetic used showed greater variability (Table 6); orthopae-
dic surgeons used significantly greater volumes (p < 0.01)
than PCSMs/PMRs and rheumatologists for the S-A bursa
and G-H joint (and these latter two physician groups were
not significantly different (p > 0.3)). This supports the sec-
ond facet of our first hypothesis.
Hypothesis 2
Among all of the specialties, the recommended corticos-
teroid dose ranges (shown in Table 2) were exceeded
mostly in the A-C joint (orthopaedists 41%; rheumatolo-
gists 44%; PCSMs/PMRs 29%). Despite these exceeded
recommended doses for the A-C joints, >98% were within
recommendations for the S-A bursa and G-H joint. In
these two locations, only a few orthopaedic surgeons
exceeded these dose ranges (4% and 2%, respectively).
Among those orthopaedic surgeons, two surgeons
injected 1.5 times the highest recommended dose for the
S-A bursa or G-H joint.
Additional considerations
Injections in the biceps tendon sheath and the trigger
points showed little to no variability among the special-
ties and are therefore given little mention in the discus-
sion and figures. However, analysis of corticosteroid types
used in these extra-articular locations showed significant
inter-specialty differences in the use of fluorinated vs.
non-fluorinated corticosteroids. Fluorinated corticoster-
oids (Table 2), which can be more deleterious to soft tis-
sues (see discussion below), were used with the following
frequencies:  Biceps sheath: 17% rheumatologists, 8%
PCSMs/PMRs, 37% orthopaedists; Trigger points: 10%
rheumatologists, 5% PCSMs/PMRs, and 34% orthopaed-
ists. In turn, the majority of physicians used non-fluori-
nated corticosteroids for each location.
The majority (85%) of all responding physicians use the
same corticosteroid for each injection site. When asked for
a rationale for using a particular corticosteroid, responses
varied widely and included: long/short acting (30.3%),
Table 4: Frequencies of corticosteroid types used by responding physicians separated into each specialty group. Combo = 
corticosteroid combinations used. Contingency Table for Most Common Corticosteroids, or Corticosteroid Combinations
Orthopaedic Surgeons
Depo-Medrol® Kenalog® Combo TOTAL
A-C Joint 43 18 9 70
S-A Bursa 35 20 13 68
G-H Joint 36 14 8 58
TOTAL 114 52 30 196
PCSMs/PMRs
Depo-Medrol® Kenalog® Combo TOTAL
A-C Joint 17 8 0 25
S-A Bursa 15 12 2 29
G-H Joint 11 10 2 23
TOTAL 43 30 4 77
Rheumatologists
Depo-Medrol® Kenalog® Combo TOTAL
A-C Joint 2305
S-A Bursa 10 6 2 18
G-H Joint 741 12
TOTAL 19 13 3 35
Combo = combinations of two or more corticosteroids.BMC Musculoskeletal Disorders 2007, 8:63 http://www.biomedcentral.com/1471-2474/8/63
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availability and/or force of habit (15.3%), faster (or
slower) onset (12.2%), lower associated pain within 48
hours of the injection (9.1%), and solubility (8.3%).
Data regarding acetate vs. phosphate types of corticoster-
oids are summarized in Table 7. Among the physicians
who used different types of corticosteroids depending on
the condition being treated, acetate types (less soluble)
were most commonly used for chronic conditions, includ-
ing arthritis, bursitis, biceps tendinitis, impingement, and
rotator cuff tendinitis. Phosphate types (more soluble)
were used more frequently in acute conditions such as
bursitis, muscle contusion, and adhesive capsulitis. More
rheumatologists (80%) were aware that there are acetate
and phosphate types of corticosteroids as compared to
PCSMs/PMRs (76%) and orthopaedic surgeons (59%).
However, relatively less rheumatologists (25%) than
PCSMs/PMRs (32%) or orthopaedic surgeons (32%)
knew that phosphate types are more soluble (Table 7).
When asked about types/volumes of local anesthetic that
they administered with corticosteroid injections, 92 phy-
sicians (74.2%) use Lidocaine (Xylocaine®) or Bupivicaine
(Marcaine®) when injecting the A-C joint. The type of local
anesthetic and the percentage of physicians who inject
them are shown in figure 2. Volumes of local anesthetic
vary considerably for all shoulder conditions, and most
significantly in the S-A bursa where the range is 0.5 cc to
10 cc (Table 6).
Only 15 physicians (10.0%) reported any change in treat-
ment for diabetic patients including two (1.3%) who do
not inject them. The number and (percentage) of physi-
cians in each group who did alter their practice for diabet-
ics are as follows: 8/93(8.6%) orthopaedists; 5/
37(13.5%) PCSMs/PMRs; 2/20(10%) rheumatologists
(Table 7 bottom). Seven physicians (4.7%, three ortho-
paedists, three PCSMs/PMRs, and one rheumatologist)
simply inject less corticosteroid for diabetics, and only
one (0.7%, an orthopaedist) physician explicitly stated
that he had these patients closely monitor their blood glu-
cose levels for one week after the injection. Claiming
fewer systemic effects, two physicians (1.3%, one ortho-
paedist and one rheumatologist) use phosphate derivative
corticosteroids for diabetic patients. None of the respond-
ing physicians varied their corticosteroid type or volume
for patients with other (non-diabetic) medical conditions.
Only six physicians (4.0%, three orthopaedists, one
PCSMs/PMRs, and two rheumatologists) used a different
corticosteroid type or dose for young athletes compared to
less active middle-aged patients. Less than 2% of all survey
respondents (two orthopaedists) injected painful (non-
arthritic) A-C and G-H joints in young patients or athletes.
Discussion
Results of our survey show that, on average, the dose
equivalents of corticosteroids used for injecting the vari-
ous shoulder regions do not differ significantly between
orthopaedic surgeons, rheumatologists, and specialty
physicians (PCSMs = primary-care sports medicine physi-
cians, and PMRs = physical medicine and rehabilitation
physicians). This contradicts one facet of our first hypoth-
esis predicting that significant differences would be found
in corticosteroid doses between these groups. Results of
our retrospective sample-size and power calculations (see
Methods) also suggest that these small differences are not
the result of statistical error. Although table 2 provides
general guidelines for recommended doses and dose
equivalents for common injectable corticosteroids, for
most shoulder conditions it is not clear how much corti-
costeroid/anesthetic is appropriate since uniform guide-
lines for these injections are not firmly established. This is
evident in the broad variations in dose ranges recom-
mended in recent literature for commonly injected loca-
tions/conditions (Table 1). The present study shows that
there is a wide variety of corticosteroid types used for each
injected location for degenerative and/or overuse condi-
tions and reported doses show a broad range within each
specialty group. However, only 3–4% of surgeons and
Corticosteroid types used by responding physicians to inject  the S-A bursa Figure 1
Corticosteroid types used by responding physicians 
to inject the S-A bursa. Data are shown as the percent of 
physicians using each corticosteroid type. Note that several 
physicians use one or two corticosteroids (but not in combi-
nation) for a given injection site (see text for details). This 
accounts for the cumulative percentage of >100% in these 
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PCSMs/PMRs use doses exceeding the "recommended"
range for the G-H joint and the S-A bursa. In contrast,
39% of all physicians (41% orthopaedic surgeons, 44%
rheumatologists, 29% PCSMs/PMRs) exceeded the rec-
ommended dose range for the A-C joint. It is possible that
the most commonly used corticosteroids, Depo-Medrol®
and Kenalog®, reflect their comparative costs in U.S. dol-
lars (e.g., $5.00 for 40 mg Depo-Medrol®; $6.90 for 40 mg
Kenalog®; $6.80 for 6 mg Celestone Soluspan®; $6.00 for
20 mg Aristospan®; $7.60 for 4 mg Decadron®).
In contrast to data for corticosteroid doses, the volumes of
local anesthetic used for injecting these painful shoulder
conditions varies significantly between the physician
groups, corroborating this facet of our first hypothesis. For
example, in the perspective of our shoulder specialty prac-
tice the amount of local anesthetic typically used by
PCSMs/PMRs and rheumatologists seems insufficient,
especially for the S-A bursa. This view is based on our use
of volumes commensurate with Neer's "impingement
test", where 10 cc of local anesthetic (1% Lidocaine) is
used to adequately infuse the S-A bursa [20]. Pain relief
with provocative maneuvers of the shoulder, indicative of
a positive test, is useful for establishing a S-A impinge-
ment lesion as the cause of pain [21]. However, most of
the physicians (predominantly non-surgeons) used less
than half of the 10 cc volume described by Neer. We spec-
ulate that the relatively smaller volume of anesthetic (5
cc) used by Kirkley et al. (2002) [22] to rigorously evalu-
ate the Neer impingement test might help to explain why
these investigators concluded that this test might be insuf-
ficient for predicting the success of surgery [23]. Recent
published recommendations for total dose/volume of
corticosteroid/anesthetic solutions also typically fall 3–6
cc short of the 11–12 cc that would be administered when
corticosteroid is added to the volume of local anesthetic
(10 cc) used in the Neer impingement test [3,4,24,25].
Infusing corticosteroid with such 'large' volumes of local
Table 6: Mean volumes [g/cc] and (standard deviation) of corticosteroid and local anesthetic. Mean volumes [cc] and (standard 
deviation) of cortisone and local anesthetic
Acromioclavicular (A-C) Joint Subacromial (S-A) Bursa Glenohumeral (G-H) Joint
Cortisonea,b Local Cortisonea,b Local Cortisonea,b Local
Rheumatologists 0.8 (0.3) 1.1 (0.5) 1.1 (0.5) 2.1 (2.1) 1.1 (0.5) 2.3 (1.5)
Sports Medicine & Physiatrists (PCSMs/
PMRs)
0.8(0.5) 1.2 (0.6) 1.4 (0.7) 3.2 (1.9) 1.4 (0.7) 3.2 (1.9)
Orthopaedic Surgeons 0.9 (1.1) 1.5c (1.4) 1.6 (2.1) 4.7c (2.8) 1.6 (2.3) 4.7c (2.6)
a 1 cc of "cortisone" (i.e., a corticosteroid of any given type) represents the equivalent of 40 mg of Depo-Medrol.
b There are no significant differences in cortisone doses between the three physician groups.
c When compared to each of the other groups, orthopaedic surgeons use significantly (p < 0.01) greater volumes of local anesthetic in each location. 
Rheumatologists and PCSMs/PMRs do not differ in anesthetic volumes (p > 0.3).
Table 5: Physician characteristics: gender and years-in-practice. Physician Characteristics (excluding late responders)
Female (%) Male (%) Years in practice % of total responding physicians 
per time interval
% of responding physicians who 
answered this question
Orthopaedists 0% 100% 0–5 7.7% (n = 7)
6–10 16.5% (n = 15)
11–15 20.9% (n = 19) 86.7%
16–20 14.3% (n = 13)
>20 40.2% (n = 37)
PCSMs/PMRs 24.4% 75.6% 0–5 16.2% (n = 6)
6–10 32.5% (n = 12)
11–15 21.6% (n = 8) 84.1%
16–20 13.5% (n = 5)
>20 16.2% (n = 6)
Rheumatologists 7.7% 92.3% 0–5 20% (n = 4)
6–10 20% (n = 4)
11–15 20% (n = 4) 100.0%
16–20 15% (n = 3)
>20 25% (n = 5)BMC Musculoskeletal Disorders 2007, 8:63 http://www.biomedcentral.com/1471-2474/8/63
Page 9 of 13
(page number not for citation purposes)
Table 7: Physician responses to selected survey questions (acetate vs. phosphate, and diabetes). Acetate vs. Phosphate, & Diabetes, 
Contingency Tables
Question #5a – Were you aware that there are acetate and phosphate types of corticosteroids?
Orthopaedists PCSMs/PMRs Rheumatologists TOTAL
Yes 55(59.1%) 28(76%) 16(80%) 99
No 36(38.7%) 9(24%) 4(20%) 49
No Answer 2(2.2%) 0(0%) 0(0%) 2
TOTAL 93 37 20 150*
Question #5b – If yes, which type is more soluble?
Orthopaedists PCSMs/PMRs Rheumatologists TOTAL
Phosphate 30(32.2%) 12(32.4%) 5(25%) 47
Acetate 6(6.5%) 3(8.1%) 2(10%) 11
Don't Know 57(61.3%) 22(59.5) 13(65%) 92
TOTAL 93 37 20 150*
Question #6 – Were you aware that acetate vs. phosphate corticosteroids may have different degrees of local and systemic absorption, and differences 
in duration of their anti-inflammatory affect?
Orthopaedists PCSMs/PMRs Rheumatologists TOTAL
Yes 40(43%) 19(51.4%) 10(50%) 69
No 51(54.8%) 16(43.2%) 10(50%) 77
No Answer 2(2.2%) 2(5.4%) 0(0%) 4
TOTAL 93 37 20 150*
Question #7 – Do you ever use acetate-type corticosteroids (instead of phosphate-types) for treating specific shoulder conditions?
Orthopaedists PCSMs/PMRs Rheumatologists TOTAL
Yes 35(37.6%) 13(35.1%) 3(15%) 51
No 49(52.7) 21(56.8%) 13(65%) 83
No Answer 9(9.7%) 3(8.1%) 4(20%) 16
TOTAL 93 37 20 150*
Question #8 – Do you ever use phosphate-type corticosteroids (instead of acetate-types) for treating specific shoulder conditions?
Orthopaedists PCSMs/PMRs Rheumatologists TOTAL
Yes 21(22.6%) 9(24.3%) 3(15%) 33
No 66(71%) 26(70.3%) 17(85%) 109
No Answer 6(6.4%) 2(5.4%) 0(0%) 8
TOTAL 93 37 20 150*
Question #9 – Do you use a different type of corticosteroids for injecting the shoulder region of diabetic patients?
Orthopaedists PCSMs/PMRs Rheumatologists TOTAL
Yes 8(8.6%) 5(13.5%) 2(10%) 15
No 85(91.4%) 31(83.8%) 18(90%) 134
No Answer 0(0%) 1(2.7%) 0(0%) 1
TOTAL 93 37 20 150*
* The total number of physicians represents the 150 of the 169 early responders who actually treat painful shoulder conditions with corticosteroids 
(93 orthopaedic surgeons, 37 PCSMs/PMRs, and 20 rheumatologists.)BMC Musculoskeletal Disorders 2007, 8:63 http://www.biomedcentral.com/1471-2474/8/63
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anesthetic may also enhance the distribution of corticos-
teroid throughout the bursa, especially when inflamma-
tory bursa separations or compartmentalization exists
[26]. In our shoulder-specialty practice we consider
'larger' volumes of local anesthetic, such as those
described by Neer [20], as an essential component for
these injections [23]. In turn, results of the present study
showing variations between specialists in anesthetic doses
suggest that surgeons (who use significantly larger anes-
thetic volumes) emphasize determining the percentage of
pain attributable to the injected region as a tool for surgi-
cal planning. However, it is also plausible that, when
compared to surgeons, non-surgeons inject lower vol-
umes of local anesthetics because they have more pro-
found knowledge of potential cardiovascular side effects
resulting from the inadvertent intra-vascular injection of
these agents. For example, there are reports of hypoten-
sion, bradycardia, and cardiac arrest resulting from the
intra-vascular injection of Bupivicaine and Lidocaine [27-
31].
Effective uniform guidelines for corticosteroid injections
must consider the possibility that doses exceeding recom-
mended ranges could cause additional systemic and local
side effects. Deleterious consequences and other sequelae
of corticosteroid injections are frequently a result of
chronic use, and may be more prevalent if the corticoster-
oid spreads to adjacent tissues [8,32,33]. Consideration
for systemic consequences are also important, especially
for patients with diseases that cause immunosupression
(e.g., diabetes mellitus and rheumatoid arthritis)
[4,16,17,34,35]. Systemic dissemination of corticosteroid
can occur after local injection, further reducing endog-
enous cortisol levels and exacerbating immunosupression
[32,36,37]. In this perspective it is interesting that only
10% (15/150) of the survey respondents (two of these
were rheumatologists) report any modifications in corti-
costeroid dose or type, or adjustments in glucose monitor-
ing for diabetic patients. In our clinical practice we have
our diabetic patients monitor their glucose levels more
closely (i.e., every six hours), and have them adjust their
medication doses for one-to-two weeks after receiving the
corticosteroid injection. Although we have observed that
insulin-dependent and non-insulin-dependent diabetic
patients can have broad fluctuations in finger-stick blood
glucose measurements (exceeding 400 mg/dL) for several
days following an S-A or G-H injection, published data on
this issue are contradictory [38,39]. Further studies are
therefore warranted for determining whether adjustments
of corticosteroid types, doses, and dose intervals are nec-
essary when injecting diabetic patients.
It has been noted in rheumatology literature that fluori-
nated corticosteroids (e.g., Celestone Phosphate®, Cele-
stone Soluspan®, Decadron®, Kenalog®, and Aristospan®)
(Table 2), when compared to non-fluorinated corticoster-
oids (e.g., Hydeltrasol®, Depo-Medrol®, Hydeltra-TBA®,
and Hydrocorticone®), are more highly associated with
tendon rupture and subcutaneous atrophy [8]. For this
reason, Moore suggests avoiding the use of fluorinated
corticosteroids for extraarticular injections [8]. This is
because soft tissue injections of these agents can cause sig-
nificant atrophy of collagenous tissue that can lead to lig-
ament or tendon rupture or subcutaneous calcification
and/or atrophy (the atrophy may disappear in 2 to 3
years). Results of our survey suggest that few physicians,
especially orthopaedic surgeons, recognize or accept the
putative importance of this issue for selecting a particular
corticosteroid type for extra-articular injections. This
seems evident in results showing that 17% of rheumatol-
ogists, 8% of PCSMs/PMRs, and 37% of orthopaedists
typically used fluorinated corticosteroids for injecting the
biceps tendon sheath, and 10% of rheumatologists, 5% of
PCSMs/PMRs, and 34% of orthopaedists use fluorinated
corticosteroids for injecting trigger points.
Our survey also queried physicians regarding whether or
not they made adjustments in corticosteroid dosing based
on patient age. The only notable finding was that less than
1% of all survey respondents injected painful (non-
arthritic) A-C and G-H joints in young patients or athletes.
This probably reflects the philosophy, common in sports
medicine literature, that performing these injections
could exacerbate the injury because pain-related percep-
Types of local anesthetics used by all responding physicians Figure 2
Types of local anesthetics used by all responding phy-
sicians. S-A bursa and G-H data are similar. N/A = not 
applicable (i.e., physicians who inject painful shoulder condi-
tions as part of their practice but who do not inject the joint 
indicated); Combo = combination of Lidocaine and Bupivic-
aine. Bupivicaine has significantly prolonged onset of anesthe-
sia (~2–10 minutes) when compared to lidocaine (seconds to 
minutes) (package product information, Abbott Laboratories, 
North Chicago, IL, USA).
Local Anesthetic Types used for Shoulder 
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tion, which helps to 'protect' the joint by limiting its use,
is diminished [32,40-42]. Similarly, it has been suggested
that pain relief from corticosteroid injections into degener-
ative  joints can accelerate the degenerative process by
allowing increased use (and further deterioration) of the
joint [40,43]. Although this idea is typically applied to
weight-bearing joints, it might also apply to the A-C and
G-H joints.
The possibility that exceeding dose ranges for intra-articu-
lar injections (as reported by ~37% survey respondents for
the A-C joint) can have deleterious effects on articular car-
tilage is, however, suggested by indirect or anecdotal evi-
dence. For example, injections of high dose (50–100 mg)
betamethasone acetate once a week for two-to-four weeks
into the knees of four-to-six month old rabbits caused dis-
tortion of articular chondrocyte shape and loss of cell
organelles, thus affecting the normal production of colla-
gen fibers responsible for articular cartilage strength
[44,45]. Subtle cell distortion was detected after only two
doses (necropsy at 28–42 days post-injection). These and
other studies showing deleterious effects in growing ani-
mals [32], however, might not be applicable when 'high'
doses are injected into degenerative joints in humans. For
example, Hollander and co-workers have shown little evi-
dence of morbidity of intra-articular corticosteroid injec-
tions that have been used for many years as a primary
treatment modality for osteoarthritis of the knee [46,47].
Owen (2001) [32] also notes that the concept of glucocor-
ticoid arthropathy is based largely on anecdotal case
reports and subprimate animal studies. By contrast, stud-
ies of primate models have shown no long-term adverse
effect on cartilage [48]. There is also a well documented
report of a 51-year-old women who received 100 gluco-
corticoid injections [using Hydeltra TBA, Celestone Solus-
pan, or Kenalog] into each knee during a span of 10 years
with no deleterious effects seen on knee radiographs taken
before and after these treatments [49]. Additionally, Balch
et al. (1977) studied knee radiographs of 65 patients with
osteoarthritis or rheumatoid arthritis who received
repeated injections extending from four to 15 years [50].
The radiographs of 15 patients showed no deterioration,
38 showed minimal to moderate deterioration, 10
showed marked deterioration, and only two showed gross
deterioration. Although twelve of these patients (12/65,
18.5%) appear to have clearly developed what some
might call "steroid arthropathy", the results in the major-
ity of these patients do not support the contention that
repeated intra-articular injections of corticosteroids into
arthritic knees would inevitably lead to rapid joint
destruction.
Even in view of these data and observations – which are
now early 20 years old – deleterious consequences of
intra-articular injections shown in studies of sub-primate
animals appear to have swayed most experts toward warn-
ing that similar consequences might also occur in degen-
erative joints in humans. As noted, our survey did not
evaluate the dosing intervals typically used by the physi-
cians in each group. Therefore, it is not clear if 'excessive'
doses – irrespective of dose intervals – used by some of
our surveyed physicians could enhance the progression of
arthritis.
Results of correlation analyses showed a tendency toward
reduced corticosteroid doses with years-in-practice in the
PCSMs/PMRs and rheumatologist groups. The strongest
relationship was found in the rheumatologists who
showed reduced corticosteroid doses for periscapular trig-
ger points (r = -0.759, p = 0.05). Additional studies would
be required to first corroborate these findings and, sec-
ond, to determine if they reflect temporal differences in
training or a trend that occurs with clinical experience. For
example, it would be interesting to determine if this trend
in trigger points reflects clinical experience that these
rheumatologists might have with subcutaneous atrophy
caused by injecting corticosteroid injections.
Limitations of our study include its regional focus on phy-
sicians in our tri-state referral area of the western United
States. Although these results may not apply to broader
geographical regions of the United States, in the context of
our literature review they do illustrate the lack of uniform
injection guidelines in the general literature. Furthermore,
our data might not reflect the injection practices of sur-
geon and non-surgeon peers outside of the United States.
Another limitation included the relatively lower response
rate of PCSMs/PMRs (56%), when compared to the
higher response rates of rheumatologists and orthopaedic
surgeons (83% and 63% respectively). Early-responder vs.
late-responder analyses did not demonstrate significant
differences within the two groups with response rates of
<65%. However, given that there were only 11 and 7
responses in these respective groups from the later mail-
ing, it is unlikely that the data in this context is suitably
powered for finding any statistically significant differ-
ences. Although these data do not rigorously rule-out
early-responder vs. late-responder bias, they tend to
reduce this possibility as a confounding factor in general-
izing the results as representative of the injection practices
of the physician groups that were surveyed. Therefore, the
current study provides useful baseline data for guiding
future studies of physicians in larger geographical areas. In
addition to aiding in establishing uniform injection
guidelines, our results also indicate the clear need for
advanced education with regards to some aspects of the
use of corticosteroid/anesthetic injections.
Future surveys that are designed for broader geographical
distribution should also consider additional medical con-BMC Musculoskeletal Disorders 2007, 8:63 http://www.biomedcentral.com/1471-2474/8/63
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ditions or concerns that were not explicitly addressed in
the present study. For example, further clarification of
clinical practice of the surgeons and non-surgeon groups
should include questions regarding whether or not they
would consider injecting, or modifying injections, in
patients taking anticoagulant medications. For example,
although many physicians might consider the concomi-
tant use of Warfarin as a contraindication of these injec-
tions, it is not know exactly how prevalent this opinion is
and/or if this opinion varies in cases where patients are
taking other types of anticoagulant medications (e.g.,
aspirin or clopidogrel bisulfate).
Conclusion
Variations shown in this study between specialists in anes-
thetic doses suggest that surgeons (who use significantly
larger anesthetic volumes) emphasize determining the
percentage of pain attributable to the injected region.
Alternatively, this might reflect a more profound knowl-
edge that non-surgeons specialists have of the potentially
adverse cardiovascular effects of these agents. Although
the ranges of corticosteroid doses for each injection loca-
tion were broad, the mean doses did not differ signifi-
cantly between the groups. Nearly 85% of the respondents
use the same corticosteroid for all injections, and fewer
than 10% make adjustments for diabetic patients. Rheu-
matologists seemed more cognizant of the clinical impor-
tance of distinguishing corticosteroids based on
fluorination vs. non-fluorination, and acetate vs. phos-
phate composition. These results help provide useful
information for future studies aimed at establishing uni-
form guidelines for treating painful shoulder conditions
with injectable corticosteroids, and for identifying knowl-
edge deficiencies that warrant advanced education. Uni-
form guidelines are important for: 1) maximizing pain
relief in patients with chronic and acute painful shoulder
conditions, 2) improving communication between sur-
geon and non-surgeon sub-specialists and general health-
care providers, 3) eliminating potentially excessive corti-
costeroid exposure and adverse events, and 4) enhancing
the localization of source(s) of pain for diagnostic/prog-
nostic purposes.
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